Arash Rezazadeh Kalebasty

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

D. George, A. Molina, D. Spigel, 2022, BMJ Open.

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

John Paul Shen, C. Sternberg, E. Heath, 2022, Journal of Clinical Oncology.

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

M. Harrison, R. Singal, D. George, 2022, Journal for ImmunoTherapy of Cancer.

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

F. Saad, E. Posadas, K. Chi, 2021, Cancer Chemotherapy and Pharmacology.

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.

F. Saad, A. Armstrong, D. Shaffer, 2021, European journal of cancer.

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

J. Bendell, D. Cho, D. George, 2021, Cancer.